Publications

Efficacy and Safety of Ixazomib plus Lenalidomidedexamethasone (Ird) Vs Placebo-Rd in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (Rrmm) by Cytogenetic Risk Status in the Global Phase Iii Tourmaline-Mm1 Study.

AuthID
P-00R-HSN

Author(s)

Richardson, PG

Avet Loiseau, H

Palumbo, A

Viterbo, L

Nagler, A

Ganly, P

Ben Yehuda, D

Miguel, JS

Rajkumar, SV

Langer, C

Berg, D

Lin, JC

Van De Velde, H

Esseltine, DL

di Baccot, A

Moreau, P

Document Type

Abstract

Year published

2016

Published

in JOURNAL OF CLINICAL ONCOLOGY, ISSN: 0732-183X

Volume: 34, Issue: 15

Conference

Annual Meeting of the American-Society-Of-Clinical-Oncology (Asco), Date: JUN 03-07, 2016, Location: Chicago, IL, Sponsors: Amer Soc Clin Oncol

Indexing

Wos^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1200/jco.2016.34.15_supp1.8018

Wos: WOS:000404711505174

Source Identifiers

ISSN: 0732-183X

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Efficacy and Safety of Ixazomib plus Lenalidomidedexamethasone (Ird) Vs Placebo-Rd in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (Rrmm) by Cytogenetic Risk Status in the Global Phase Iii Tourmaline-Mm1 Study.

Useful Links

Get Help

Federated Authentication (Click on the image)

Efficacy and Safety of Ixazomib plus Lenalidomidedexamethasone (Ird) Vs Placebo-Rd in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (Rrmm) by Cytogenetic Risk Status in the Global Phase Iii Tourmaline-Mm1 Study.

Useful Links

Get Help